elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q48238170-2B109770-EC0C-49FA-8161-95125AEF3FDD
Q48238170-2B109770-EC0C-49FA-8161-95125AEF3FDD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48238170-2B109770-EC0C-49FA-8161-95125AEF3FDD
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
P2860
Q48238170-2B109770-EC0C-49FA-8161-95125AEF3FDD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48238170-2B109770-EC0C-49FA-8161-95125AEF3FDD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
966b69ccec3dab314eda98c1b2e8aa8f75d8e0d7
P2860
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.